Member Info for Naewise

Good idea Saintsmith. DA's last and only presentation to shareholders was, shall we say, not what one would expect from someone in his position. He may have been under the weather and come in from a morning tidyng up his shed but did he leave anyone punching the air with excitement? Hardly! I think shareholders deserve more than this - a lot more as one is left with almost a feeling of distrust and this from a concern which still has so much going for it - we think! I fully support this approach.

@gizm0555 - 'data from 3 sinovac jabs not encouraging'. If this is true, much of Africa must also be in peril especially as their 'winter' is 3-4 months away.

Share Risers
Price Change
Ironveld (IRON)
1.225 +38.42%
Novacyt (NCYT)
211.00 +24.45%
Caspian Sunrise (CASP)
5.05 +20.24%
Skinbiotherap. (SBTX)
44.25 +19.59%
Blue Star (BLU)
0.46 +19.48%

Pity we do not (as yet) have a home testing kit and steal a march on the opposition ..... 'As the Northern hemisphere approaches the 2021-2022 flu season, Novacyt has carried out an analysis of recent influenza genome sequences using its specialist bioinformatics surveillance expertise to determine how significant the genetic drift was in the virus from
the previous year. Through this analysis, Novacyt detected significant mutations in published sequences of the influenza B (flu B) virus and developed a new Winterplex™ test to address the new flu B strain for the 2021-2022 winter flu season. The new Winterplex™ test combines flu B, three-gene COVID-19, flu A and RSV assays in a single kit to provide clinicians and laboratories with a comprehensive testing solution. The test is designed for use in central laboratories with open PCR platforms.'

Pity we do not (as yet) have a home testing kit and steal a march on the opposition ..... 'As the Northern hemisphere approaches the 2021-2022 flu season, Novacyt has carried out an analysis of recent influenza genome sequences using its specialist bioinformatics surveillance expertise to determine how significant the genetic drift was in the virus from
the previous year. Through this analysis, Novacyt detected significant mutations in published sequences of the influenza B (flu B) virus and developed a new Winterplex™ test to address the new flu B strain for the 2021-2022 winter flu season. The new Winterplex™ test combines flu B, three-gene COVID-19, flu A and RSV assays in a single kit to provide clinicians and laboratories with a comprehensive testing solution. The test is designed for use in central laboratories with open PCR platforms.'

Page 17 by Ben Spencer - 'Technology existsin which a Lateral Flow Test could give a result not just for Covd but also for flu and RSV, two respiratory viruses that place huge pressure on the NHS each winter. Instead of showing two lines - one control line and a second line for a positive Covidresult - they would have four lines, with one for RSV and one for flu. In the future, anyone with a cough or a cold could take such a test.' He also says that it woud be unwise to dismantle pop up testing cntres and that it would make sense to boost dwindling childhood vaccination rates or repurpose them as cancer screening centres as Britain has one of the worst cancer survival rates in the West because too many tumours are spotted too late etc. ' We tend to be fascinated by our own health and, driven bythis curiosity and a widespread sense of the comon good, and directed by clear guidance, many people would continue to take tests. The diagnostic infrastruture is one of the success stories of the pandemic. It should be harnessed, not thrown away.' Cannot argue with any of this and I imagine Nova could benefit big time but is Boris listening!

So much for his 'retirement'. Wonder if he is still holding on to his last considerable purchase of NCYT at £8 plus! We will never know the real reason behind his departure which was extremely odd to say the least.

RBMInvest. A sobering post with which I largely agree. Many of us have been like ostriches with heads in the sand and far too attached to Nova. I am sure the company will progress further but may take several years. I am in the process of selling half my holding at a 62% horrific loss which is my own fault being too attached to the share and over invested losing most of my life savings. I should have known better. Time to try and recuperate elsewhere. GLA.

Courtesy gggg 2120 from the SNG forum: https://www.bloomberg.com/news/newsletters/2022-01-29/new-u-s-task-force-prepares-for-next-outbreak

It could be any day now but on the other hand we may well have to wait until end of Feb which in my book still comes under Buzz's early 2022 statement. I am extremely guarded in my optimism re potential optimism -- just look at the NCYT debacle and this from a company with £100m in the bank and money still pouring in. I am 60% down. AIM stocks have proved a graveyard for investors numerous times so I suggest folk just be a little wary. For the record, I have invested witth SNG for a year and am not a deramper just someone who urges caution. All that glitters is not necessarlty gold!

£1.58 now -- who would have thought it. Frankly there seems no limit to the drop in this share. What a disaster. I scoffed when Shaun P sold out in a huff at £4 plus after the DHSC debacle -- he must be laughing his head off now. NCYT is like the poverbial albatross around one's neck and I am suffering big time like so many on this forum. I would jump at £4 now and move on to pastures new.

Thanks only1Ranger.

This may sound an odd question but would treatment for Asthma warrant a lower or higher degree of efficacy from P3 result than Covid my thinking being that should the degree of P3 result be less than hoped for Covid (I am sure it won't be), it would nevertheless still be extremely advantageous regards Asthma. You can perhaps see where I am coming from as Asthma must be a massive market which has been around for donkeys years and unlikely to disappear.

Good point Sir D -- silly me!

There is understandably much bitterness following yesterday's RNS but why do some regular posters consistently engage with the increasing numbers of Trolls determined to diminish the SP? You must surely either have far too much time on your hands or insist on having the last word. You are doing this forum no favours by pandering to these sad people so why not bin them and give the rest of us a break from the continual sniping and concentrate on the future prospects of this concern? DA looked ill yesterday and although he gave reasonably decent replies to questions, he hardly left me punching the air with excitement. QUESTION: How many non Covid products if any are awaiting CDTA approval? I suspect now that DA has shown his face to PIs, we will see more of him before April given his marketing background. He will want, hopefully, to give a more upbeat performance and cannot be too happy with yesterday's effort. We appear to have an extremely strong team and what with a DHSC settlement of sorts possible soon , I can see Nova drag itself slowly out of the mire, heading towards a bright future.

Really? Try telling Synairgen (SGN) just days away from revealing potential life saving results from P3 trials with a potential world beating treatment for Covid and Asthma!

To continue in R and D to develop Respiratory Products etc is surely a new and exciting development?

...for SNG to publish P3 results whilst power mad Putin is poised on invading Ukraine. Even if results were spectacular I doubt the SP would soar much if anything and publicity could be muted. Better to wait a few weeks more until the dust settles -- hopefully!

Should not be surprised the SP is approaching £2.50 even with results due despite likely healthy sales. What concerns me is the seeming almost total lack of news on any of the various exciting areas we are told exist. Most companies of repute would have managed to give some sort of feedback by now but not Nova so one has to speculate what game BODS are playing or is the simple truth that there has been no real progress hence the continued collapse in SP. No wonder IIs are keeping a wide berth and I must confess I am becoming rather distrustful of our new CEO -- what is he hiding?

£2.10